7(top 2%)
Impact Factor
7.7(top 2%)
extended IF
64(top 6%)
H-Index
2K
authors
1.3K
papers
24.1K
citations
2K
citing journals
18.9K
citing authors

Most Cited Articles of Blood Cancer Journal

TitleYearCitations
'Acute myeloid leukemia: a comprehensive review and 2016 update'2016542
Acute lymphoblastic leukemia: a comprehensive review and 2017 update2017436
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion2018221
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia2014183
Acute promyelocytic leukemia: where did we start, where are we now, and the future2015164
Pathogenesis of bone disease in multiple myeloma: from bench to bedside2018144
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts2016130
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites2013130
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors2015129
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study2019126
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia2015123
Interpretation of cytogenetic results in multiple myeloma for clinical practice2015121
CAR-T cell therapy: current limitations and potential strategies2021119
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria2018115
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing2012115
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients2014114
Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update2011114
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF42015113
CircRNAs in hematopoiesis and hematological malignancies2016105
PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival2015102
Myeloma cells suppress osteoblasts through sclerostin secretion2011100
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma201799
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting201897
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution201595
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation201590